| Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda (NCT00639938) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-07-01 |
| HIV-HCV Coinfection: Impact of Immune Dysfunction (NCT00575315) | Virginia Commonwealth University | 2004-07-01 |
| Evaluation of Atazanavir Substitution Intervention (EASI) Study (NCT00247845) | University of British Columbia | 2004-07-01 |
| A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients (NCT00089492) | Hoffmann-La Roche | 2004-07-01 |
| Effect of Medication Diaries on Adherence to Highly Active Antiretroviral Drugs Among HIV-1 Infected Kenyan Children (NCT00194545) | University of Washington | 2004-07-01 |
| Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV (NCT00122486) | FHI 360 | 2004-07-01 |
| Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV (NCT00086359) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-07-01 |
| Sleep, HIV Disease Progression, and Function in HIV Infected Children and Adolescents (NCT00253695) | Baylor College of Medicine | 2004-07-01 |
| Rapid HIV Testing for Emergency Department Patients (NCT00676481) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-07-01 |
| Atazanavir/Ritonavir Maintenance Therapy (NCT00084019) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-07-01 |
| Blood Levels of Abacavir in HIV Infected Adolescents (NCT00087945) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-07-01 |
| Yoga for Treating People at Risk for Diabetes or With Both HIV and Depression (NCT00090506) | National Center for Complementary and Integrative Health (NCCIH) | 2004-07-01 |
| ADAPT-POL: Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques (NCT00252083) | Centers for Disease Control and Prevention | 2004-07-01 |
| Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks (NCT00705705) | Medical College of Wisconsin | 2004-07-01 |
| Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents (NCT00075907) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-07-01 |
| A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions (NCT00144248) | Boehringer Ingelheim | 2004-06-25 |
| Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123) (NCT00113282) | French National Agency for Research on AIDS and Viral Hepatitis | 2004-06-01 |
| Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients (NCT00085917) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-06-01 |
| Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV (NCT00256828) | Clinical Trial Agency of HIV Study Group | 2004-06-01 |
| QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection (NCT00232908) | Hoffmann-La Roche | 2004-06-01 |
| Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients (NCT00084253) | Bristol-Myers Squibb | 2004-06-01 |
| HIV Prevention Among Substance Abusing SMI (NCT00447720) | University of Pennsylvania | 2004-06-01 |
| Effect of Tenofovir DF on Bone Metabolism in Children (NCT00088309) | National Cancer Institute (NCI) | 2004-06-01 |
| Antihyperlipidemic Effects of Oyster Mushrooms (NCT00069524) | National Center for Complementary and Integrative Health (NCCIH) | 2004-06-01 |
| Preventing HIV/Aids in Drug Abusing Youth (NCT00680719) | Oregon Research Institute | 2004-06-01 |
| HIP: HIV Intervention for Providers (NCT00164398) | Centers for Disease Control and Prevention | 2004-06-01 |
| Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression (NCT02191202) | Boehringer Ingelheim | 2004-06-01 |
| Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients (NCT00466180) | University Hospital, Caen | 2004-06-01 |
| Trial of Vitamins Among Children of HIV-infected Women (NCT00197730) | Harvard School of Public Health (HSPH) | 2004-06-01 |
| Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients (NCT00080106) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-06-01 |
| Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients (NCT00082628) | EMD Serono | 2004-05-28 |
| Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers (NCT00083330) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-05-18 |
| Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options (NCT00144287) | Boehringer Ingelheim | 2004-05-01 |
| "The Once A Day Protease Inhibitor Regimens" (NCT00242216) | The University of Texas Health Science Center, Houston | 2004-05-01 |
| Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients (NCT00082498) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-05-01 |
| Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients (NCT00001131) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-05-01 |
| An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. (NCT00933205) | Boehringer Ingelheim | 2004-05-01 |
| A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen (NCT00135395) | Bristol-Myers Squibb | 2004-05-01 |
| Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers (NCT00110591) | CytoDyn, Inc. | 2004-04-16 |
| Hepatitis B Vaccination in HIV-infected Persons (NCT00230061) | Erasmus Medical Center | 2004-04-01 |
| Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission (NCT00115648) | Johns Hopkins Bloomberg School of Public Health | 2004-04-01 |
| Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults (NCT00061243) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-04-01 |
| Directly Observed Therapy in High Risk Populations in Newark, NJ (NCT00285883) | Saint Michael's Medical Center | 2004-04-01 |
| Directly Observed Therapy in HIV Infected Adolescent Focus Groups (NCT00079729) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-04-01 |
| Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients (NCT00184951) | Radboud University Medical Center | 2004-04-01 |
| Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients (NCT00318123) | Germans Trias i Pujol Hospital | 2004-04-01 |
| Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure (NCT02232581) | Boehringer Ingelheim | 2004-04-01 |
| Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project) (NCT00643903) | University of California, San Francisco | 2004-04-01 |
| Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission (NCT00213083) | Population Council | 2004-04-01 |
| A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment (NCT00145795) | University of Chicago | 2004-04-01 |
| Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults (NCT00090077) | GlaxoSmithKline | 2004-04-01 |
| A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen (NCT00135343) | Bristol-Myers Squibb | 2004-04-01 |
| Combination Vaccination Before HIV Treatment Interruption (NCT00212888) | Ottawa Hospital Research Institute | 2004-04-01 |
| Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP (NCT00076037) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-04-01 |
| Daclizumab to Treat HIV-Infected Patients (NCT00080431) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-03-26 |
| HIV Vertical Transmission in Vietnam (NCT00669604) | National Institute of Hygiene and Epidemiology, Vietnam | 2004-03-01 |
| Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) (NCT00146419) | Centers for Disease Control and Prevention | 2004-03-01 |
| Breastfeeding, Antiretroviral, and Nutrition Study (NCT00164736) | Centers for Disease Control and Prevention | 2004-03-01 |
| TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 (NCT00089700) | Tanox | 2004-03-01 |
| Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial (NCT00429845) | Hospital de Clinicas de Porto Alegre | 2004-03-01 |
| Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants (NCT00076791) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-03-01 |
| A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines (NCT00076063) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-03-01 |
| Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection (NCT00127959) | International Antiviral Therapy Evaluation Center | 2004-03-01 |
| Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors (NCT00730223) | Vanderbilt University | 2004-03-01 |
| HIV Prevention Program for Patients Receiving Care at a Sexually Transmitted Diseases Clinic (NCT00183573) | The Miriam Hospital | 2004-03-01 |
| HIV Antiretroviral Drugs and Metabolism (NCT00525239) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2004-03-01 |
| The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients (NCT00400738) | The HIV Netherlands Australia Thailand Research Collaboration | 2004-03-01 |
| A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients (NCT00002207) | Bristol-Myers Squibb | 2004-02-01 |
| Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission (NCT00099359) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2004-02-01 |
| Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection (NCT00164060) | Bayside Health | 2004-02-01 |
| A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients. (NCT00144105) | Boehringer Ingelheim | 2004-02-01 |
| 2NN & CHARM Long-Term Follow-up Study (NCT00127972) | International Antiviral Therapy Evaluation Center | 2004-02-01 |
| Emotional Disclosure in HIV (NCT00067704) | University of Miami | 2004-02-01 |
| A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection (NCT02582983) | Hoffmann-La Roche | 2004-02-01 |
| Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV (NCT00084149) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-02-01 |
| Leukapheresis for Research on HCV-Coinfected Patients (NCT00076427) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-01-14 |
| Long Term Treatment Interruptions (NCT00433056) | A.O. Ospedale Papa Giovanni XXIII | 2004-01-01 |
| Factors Affecting Adherence to Anti-HIV Drug Regimens in Children and Adolescents (NCT00073424) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-01-01 |
| GW873140 to Treat HIV-1 Infected Adults (NCT00076284) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-01-01 |
| 3TC or No 3TC for HIV With 3TC Resistance (NCT00143728) | University of British Columbia | 2004-01-01 |
| Trial of SAVVY and HIV in Ghana (NCT00129532) | Biosyn | 2004-01-01 |
| Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia (NCT00246376) | Baylor College of Medicine | 2004-01-01 |
| Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression (NCT00336778) | University of Maryland, Baltimore | 2004-01-01 |
| Managing Medications (NCT00222716) | University of Pittsburgh | 2004-01-01 |
| An Observational Study of People Who Have Recently Been Infected With HIV (NCT00103961) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-01-01 |
| Physiologic Growth Hormone Effects in HIV Lipodystrophy (NCT00100698) | Massachusetts General Hospital | 2004-01-01 |
| Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein (NCT00529698) | Istituto Superiore di Sanità | 2004-01-01 |
| Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy (NCT00312832) | Hospital Clinic of Barcelona | 2004-01-01 |
| Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia (NCT00160329) | Stanford University | 2004-01-01 |
| Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir (NCT00120393) | Bristol-Myers Squibb | 2004-01-01 |
| Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119) (NCT00120185) | French National Agency for Research on AIDS and Viral Hepatitis | 2003-12-01 |
| Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men (NCT00231972) | Fenway Community Health | 2003-12-01 |
| Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults (NCT00069030) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-12-01 |
| A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV (NCT00529971) | Mount Sinai Hospital, Canada | 2003-12-01 |
| A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects (NCT00075231) | Abbott | 2003-12-01 |
| Randomized Controlled Trial of Stress Management Training in HIV (NCT00436085) | University of Zurich | 2003-12-01 |
| Positive Choice: Prevention for Positive Health (NCT00447707) | National Institute on Drug Abuse (NIDA) | 2003-12-01 |
| Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS (NCT00505401) | Istituto Superiore di Sanità | 2003-12-01 |
| Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies (NCT00311688) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-12-01 |
| Share Safer Sex Counseling Program for Changing Sexual Risk Behaviors in Mexican Female Sex Workers (NCT00338845) | University of California, San Diego | 2003-12-01 |